BRAF and melanoma: As shown in Figure 4 treatment with LY294002 (25 μM) was able to significantly decrease the number of Cdc42(G12V) colonies (p < 0.001), suggesting that PI3K is important for activated Cdc42(G12V) anchorage-independent growth in BRAF-mutant melanoma.